In anticipation of FDA approval of psychedelics for commercial medical use, our team of frontline psychedelic clinicians and researchers offers evidence-informed training programs and consultancy packages to build the optimal clinical setting needed to deliver psychedelic treatment safely, effectively and efficiently.
Explore
Synchrony delivers training and consultation to organizations seeking to conduct psychedelic research, provide psychedelic treatment and deliver psychedelic therapy training programs. We are a team of expert psychedelic clinicians, researchers, and trainers with the unique experience of providing front-line legal psychedelic treatment to mental health populations and developing indication-specific treatment protocols in some of the largest psychedelic trials to date.
To mitigate potential risks and to promote ethical and efficacious clinical practice in psychedelic treatment, evidence-informed therapeutic support from skilled clinicians is crucial and in high demand. Equally important to patient safety and durable clinical outcomes is the treatment setting, the values and intentions guiding clinical practice, and the organizational culture holding patients and providers as one.
In anticipation of approval of psychedelic treatment, specialist clinics with optimized health care infrastructure will be needed to deliver psychedelic care and meet the needs of countless patients failed by current therapeutics. To meet these demands, Synchrony guides and supports the development of the next generation of clinicians and organizations shaping the future of psychedelic therapy.
Maghsoudi M, Tanguay J,Scarfone K,Rammohan I, Ziegler C, Werb D, Scheim A. (2021) Drug Checking Services for People Who Use Drugs: A Systematic Review. Society for the Study of Addiction. (PDF)
Barbanoj MJ, Riba J, Clos S, Gimenez S, Grasa E, Romero S (2008) Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl) 196: 315-326 (PDF)
Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl) 207: 73-83 (PDF)
Bouso JC, Doblin R, Farre M, Alcazar MA, Gomez-Jarabo G (2008) MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoactive Drugs 40: 225-236 (PDF)
Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007) Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195: 415-24 (PDF)
